Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fell 0.25% to 19,583.83. The S&P 500 also ...

TECX stock reached a new 52-week high this week, with shares trading at an impressive $53.6. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from ...

European shares were higher today. The eurozone's STOXX 600 rose 0.6%, Germany's DAX 40 gained 0.2% and France's CAC 40 ...

Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

Tectonic Therapeutic (TECX) stock surges on positive interim data from Phase 1b trial for lead candidate TX45 in patients ...

Nurses and home and health agency owners alike have told us that our AI powered app is a gamechanger. With our recent enterprise wins in this $130 Billion sector 1, we believe that we have a solution ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

In a report released yesterday, Tiago Fauth from Wells Fargo reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report), with a ...